pharma · Achondroplasia · Amyloid Cardiomyopathy, Transthyretin-Related · BBOT
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker BBOT. Primary therapeutic focus areas include Achondroplasia, Amyloid Cardiomyopathy, Tra
256 E Grand Ave, Suite 104, South San Francisco, California 94080, US HQ
103 Employees
Public company Type
BBOT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 256 E Grand Ave, Suite 104, South San Francisco, California 94080, US
- Employees
- 103
- Programs
- 34
- Drugs
- 14
- Patents
- 1
ALXN2060
Phase 3 · small molecule · Symptomatic Transthyretin Amyloid Cardiomyopathy
ALXN2060 for Symptomatic Transthyretin Amyloid Cardiomyopathy is a Phase 3 program (small_molecule) at BridgeBio Oncology Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code ALXN2060-TAC-302
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BridgeBio Oncology Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Symptomatic Transthyretin Amyloid Cardiomyopathy
- Status
- completed
- Trials
- 1